Miramontes Capital’s Cue Biopharma CUE Stock Holding History

Miramontes Capital’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-868	Closed	-$5.99K	–	142
2026 Q1	$5.99K	Hold	868	–	–	﹤0.01%	122
2025 Q4	$7.95K	Buy	+868	New	+$15.9K	﹤0.01%	126

Other funds holding CUE

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Capital Management

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return

Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Squadron Capital Management Westmont, Illinois $322M AUM

Miramontes Capital's CUE Position: Q2 2026 in Review

Miramontes Capital sold out of Cue Biopharma (CUE) in Q2 2026, closing a stake of 868 shares — an estimated $5.99K sold.

Miramontes Capital first reported a position in CUE in Q4 2025 and held it in 2 quarters. The position peaked at $7.95K in Q4 2025. 50 funds tracked by Wall St. Rank hold CUE as of Q2 2026.

Miramontes Capital reported no remaining Cue Biopharma position as of Q2 2026 after selling out during the quarter.
Miramontes Capital sold 868 Cue Biopharma shares in Q2 2026, an estimated $5.99K.
Miramontes Capital first reported a position in Cue Biopharma in Q4 2025 and held it in 2 quarters.
Miramontes Capital's Cue Biopharma position peaked at $7.95K in Q4 2025.
50 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2026.

Based on Miramontes Capital's 13F filing for Q2 2026, filed 9 Sep 2026.